Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROspect: Olaparib for HRR-mutated metastatic castration-resistant prostate cancer after novel hormonal therapy
ChiCTR2200058168Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Comprehensive response rate. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
olaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR2200058168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058168.